Top 10 Clinical Trends for July 2015

Ryan Syrek

Disclosures

July 22, 2015

#5 Clinical Trend: High Alkaline Phosphatase

Intercept Pharmaceuticals, Inc. announced submission of a new drug application to the US Food and Drug Administration (FDA). The company is seeking approval of obeticholic acid to treat primary biliary cirrhosis (PBC). Alkaline phosphatase (ALP) levels are elevated in patients with PBC, and this corresponds to an increased risk of liver failure among other serious concerns. This drug would attempt to correct for that elevation and could be an important tool.

For more in-depth clinical information, see Primary Billiary Cirrhosis.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....